Published in Arzneimittelforschung on January 01, 2000
Pharmacological characterization of M1 muscarinic acetylcholine receptor-mediated Gq activation in rat cerebral cortical and hippocampal membranes. Naunyn Schmiedebergs Arch Pharmacol (2013) 1.38
Role of hyperglycaemia in the pathogenesis of hypotension observed in type-1 diabetic rats. Int J Exp Pathol (2008) 0.77
P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J (1998) 3.23
Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther (1991) 2.55
PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol (1992) 2.43
PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol (1993) 1.69
Judging social issues: difficulties, inconsistencies, and consistencies. Monogr Soc Res Child Dev (1991) 1.56
[Structure-activity relationship of N-methyl-3-pyrroline and N-methyl-pyrrolidine-3-carboxylic acid]. Arzneimittelforschung (1971) 1.40
Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.36
[Structure-activity relationships of unsaturated esters of arecaidine and dihydroarecaidine]. Arzneimittelforschung (1973) 1.35
Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors. Br J Pharmacol (1994) 1.27
Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels. Br J Pharmacol (1994) 1.27
Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int (1997) 1.27
Modelling of mortality data from a multi-centre study in Japan by means of Poisson regression with error in variables. Int J Epidemiol (1997) 1.26
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr (1982) 1.26
Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes. Br J Pharmacol (1986) 1.22
Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet (1981) 1.22
Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br J Pharmacol (1994) 1.18
Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.18
Fluorimetric determination of oxprenolol in plasma by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.17
p-fluoro-hexahydro-sila-difenidol: the first M2 beta-selective muscarinic antagonist. Eur J Pharmacol (1988) 1.16
Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int (1999) 1.14
Functional assessments for decision-making regarding return to sports following ACL reconstruction. Part II: clinical application of a new test battery. Knee Surg Sports Traumatol Arthrosc (2015) 1.14
Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine. Eur J Pharmacol (1987) 1.13
The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. Neuropharmacology (2000) 1.12
Pharmacological characterization of the vascular muscarinic receptors mediating relaxation and contraction in rabbit aorta. J Pharmacol Exp Ther (1991) 1.12
Comparison of affinities of muscarinic antagonists to pre- and postjunctional receptors in the guinea-pig ileum. Eur J Pharmacol (1984) 1.08
Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem (1994) 1.07
Effect of flavonol derivatives on the carrageenin-induced paw edema in the rat and inhibition of cyclooxygenase-1 and 5-lipoxygenase in vitro. Arch Pharm (Weinheim) (2000) 1.06
Vitamin D: do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe. Osteoporos Int (2012) 1.05
Vitamin C concentrations in plasma as a function of intake: a meta-analysis. Int J Vitam Nutr Res (2000) 1.05
Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors. Neuropharmacology (1999) 1.05
Use of smokeless tobacco and cigarettes--effects on plasma levels of antioxidant vitamins. Int J Vitam Nutr Res (1993) 1.04
Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. Eur J Pharmacol (1989) 1.01
Muscarinic receptors mediating acid secretion in isolated rat gastric parietal cells are of M3 type. Gastroenterology (1990) 1.00
Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother (1987) 0.99
NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.97
Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum. Br J Pharmacol (1995) 0.96
Presynaptic muscarinic receptors mediating inhibition of neurogenic contractions in rabbit vas deferens are of the ganglionic M1-type. Eur J Pharmacol (1988) 0.96
Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry (2008) 0.95
Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br Med J (Clin Res Ed) (1983) 0.95
[On the microbiological conversion of N-containing substrates. 4. On the microbiological conversion of 5-hydroxyindole through Clavic eps purpurea, Cordyceps militaris and Aspergillus oryzae]. Arch Pharm Ber Dtsch Pharm Ges (1968) 0.95
o-Methoxy-sila-hexocyclium: a new quaternary M1-selective muscarinic antagonist. Eur J Pharmacol (1988) 0.95
Cefodizime penetration into skin suction blister fluid following a single intravenous dose. Eur J Clin Pharmacol (1986) 0.95
The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. Eur J Clin Pharmacol (2006) 0.95
Atenolol interaction with aspirin, allopurinol, and ampicillin. Clin Pharmacol Ther (1983) 0.94
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther (1999) 0.94
NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. Eur J Pharmacol (1998) 0.94
Different binding affinities of NMDA receptor channel blockers in various brain regions--indication of NMDA receptor heterogeneity. Neuropharmacology (1995) 0.94
Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol (1995) 0.94
Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol (1997) 0.93
Vasoconstrictor responses via P2X-receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery. Br J Pharmacol (1997) 0.93
Characterization of the prejunctional muscarinic receptors mediating inhibition of evoked release of endogenous noradrenaline in rabbit isolated vas deferens. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.93
Tocopherols and 6-hydroxy-chroman-2-carbonitrile derivatives inhibit vascular smooth muscle cell proliferation by a nonantioxidant mechanism. Arch Biochem Biophys (1995) 0.93
Synthesis of adenosine triphosphate in respiration-inhibited submitochondrial particles induced by microsecond electric pulses. Proc Natl Acad Sci U S A (1981) 0.93
Increase in magnesium plasma level after orally administered trimagnesium dicitrate. Eur J Clin Pharmacol (1996) 0.92
Characterization of muscarinic receptors mediating vasodilation in rat perfused kidney. Eur J Pharmacol (1993) 0.92
Human HT-29 colon carcinoma cells contain muscarinic M3 receptors coupled to phosphoinositide metabolism. Eur J Pharmacol (1989) 0.92
No significant effects of lutein, lycopene or beta-carotene supplementation on biological markers of oxidative stress and LDL oxidizability in healthy adult subjects. J Am Coll Nutr (2001) 0.92
Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.92
Limitation on the use of amiloride in early renal failure. Eur J Clin Pharmacol (1985) 0.92
Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol (2000) 0.91
[Fluorimetric determination of amiloride in human plasma using thin-layer chromatography]. J Chromatogr (1982) 0.91
[Fluorometric determination of propranolol and its metabolite n-desisopropylpropranolol in plasma and urine by direct meausrement of thin-layer chromatographic plates (author's transl]. J Chromatogr (1977) 0.91
Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. Life Sci (1995) 0.91
In vitro antispasmodic compounds of the dry extract obtained from Hedera helix. Planta Med (1997) 0.91
(6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem (1994) 0.91
Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung (1994) 0.90
The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr Med Chem (2001) 0.90
Bioavailability study of two different verapamil formulations. Arch Pharm (Weinheim) (1992) 0.90
1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase. J Med Chem (2000) 0.90
Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol (1999) 0.89
The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X(1) receptors. Eur J Pharmacol (2000) 0.89
A comparison of the antimuscarinic effects of pirenzepine and N-methylatropine on ganglionic and vascular muscarinic receptors in the rat. Life Sci (1984) 0.89